What supplements can be used as adjuncts for withdrawal and maintenance from kratom, cannabis, alcohol, and opioid use?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Supplements for Withdrawal and Maintenance from Kratom, Cannabis, Alcohol, and Opioids

For alcohol withdrawal, thiamine (vitamin B1) supplementation is essential and should be prescribed routinely to prevent Wernicke's encephalopathy; for opioid withdrawal, no specific supplements are recommended as first-line treatment—instead, use pharmacological adjuvants like clonidine, gabapentin, or trazodone to manage withdrawal symptoms. 1, 2

Alcohol Withdrawal and Maintenance

Essential Supplementation

  • Thiamine (Vitamin B1) is mandatory for all patients undergoing alcohol withdrawal 1
    • 30-80% of alcohol-dependent individuals show clinical or biological signs of thiamine deficiency
    • Oral thiamine for standard cases
    • Parenteral (IV/IM) thiamine for high-risk patients: malnourished, severe withdrawal, or suspected Wernicke's encephalopathy 3
    • The evidence level is low, but the benefit-risk ratio is highly favorable

Pharmacological Treatment (Not Supplements)

  • Benzodiazepines remain the reference drug class for alcohol withdrawal management 1, 3
  • For maintenance: acamprosate, naltrexone, or disulfiram are evidence-based options 1, 3, 4
  • Acamprosate has the strongest evidence for maintaining abstinence in primary care settings 4

Clinical Pitfall: Over 70% of cirrhotic patients may not require benzodiazepines for withdrawal—use symptom-adapted dosing rather than fixed protocols 1

Opioid Withdrawal and Maintenance

Pharmacological Adjuvants (Not Traditional Supplements)

No vitamin or mineral supplements are recommended as primary treatment for opioid withdrawal. Instead, use these medications to mitigate withdrawal symptoms 2:

  • α2-Agonists (first-line for withdrawal symptoms):

    • Clonidine: directly attenuates opioid withdrawal but may cause hypotension—start with small doses and titrate carefully
    • Tizanidine: less effective but safer regarding blood pressure
    • Lofexidine: FDA-approved specifically for opioid withdrawal symptoms

  • Symptomatic Relief Medications 2:

    • Gabapentin: for anxiety, insomnia, irritability
    • Trazodone: for insomnia and anxiety
    • Tricyclic antidepressants: for mood and sleep disturbances
    • Mirtazapine: for anxiety and insomnia
    • Loperamide: for GI symptoms (use cautiously—can be abused and cause arrhythmias at high doses)

Medication-Assisted Treatment for Maintenance

  • Buprenorphine/naloxone (Suboxone) is the most effective approach, reducing overdose death by up to threefold 2, 5
  • Methadone or naltrexone are alternatives 6, 5
  • These are medications, not supplements, but represent the standard of care

Critical Point: The goal is preventing withdrawal distress, not rapid detoxification. Withdrawal symptoms should be "preempted and treated with liberal use of adjuvant agents" 2

Kratom Withdrawal and Maintenance

Evidence-Based Treatment

Buprenorphine-naloxone (Suboxone) is the most promising treatment for kratom dependence 7:

  • Kratom alkaloids (mitragynine, 7-hydroxymitragynine) act as partial mu-opioid agonists
  • Withdrawal symptoms mirror opioid withdrawal: myalgia, anxiety, depression, insomnia, GI distress, lacrimation, restlessness 7
  • Sublingual buprenorphine-naloxone for detoxification and maintenance therapy

Alternative Detoxification Protocols 7

  • Intravenous clonidine (inpatient setting)
  • Combination of oral dihydrocodeine and lofexidine (inpatient setting)

Important Caveat: Kratom is often used by individuals attempting to self-treat opioid withdrawal 8, 9, 10. While 41% of kratom users report using it to reduce opioid use, kratom itself can cause dependence (though only 2% met criteria for moderate/severe kratom use disorder) 8. Co-use with cannabis is extremely common (>92% of kratom users) 11.

Cannabis Withdrawal

Evidence Gap

No specific supplements or pharmacological treatments are recommended in the provided guidelines for cannabis withdrawal. The evidence focuses on:

  • Behavioral therapies as primary treatment 12
  • No FDA-approved medications for cannabis use disorder 6

Clinical Reality: Cannabis withdrawal syndrome exists (irritability, anxiety, insomnia, decreased appetite) but is generally mild and self-limited. Symptomatic treatment with sleep aids or anxiolytics may be considered, but this is not guideline-supported.

Cross-Substance Considerations

Combined Approach

Pharmacotherapy plus cognitive behavioral therapy (CBT) or another evidence-based therapy is superior to usual care alone 12:

  • This applies across alcohol and opioid use disorders
  • CBT performs equivalently to other evidence-based therapies (motivational enhancement, contingency management)
  • The combination is more effective than medication or therapy alone

Protracted Withdrawal Syndrome

Months after substance elimination, patients may experience 2:

  • Dysphoria, irritability, insomnia, anhedonia
  • These symptoms must be anticipated and treated
  • Cannot be easily differentiated from underlying chronic conditions

Key Clinical Principle: Slow tapers (10% per month or slower for long-term users) with aggressive symptom management prevent dropout and improve long-term outcomes 2. Fear of withdrawal is a major barrier to treatment success—address it proactively with adequate pharmacological support.

References

6
Guideline

a primary care approach to substance misuse.

American family physician, 2013

Related Questions

Does Kratom (Mitragyna speciosa) cause nephrotoxicity or impaired renal function?
Is it safe to combine gabapentin with kratom?
What is the recommended treatment protocol for an adult experiencing kratom withdrawal, including medication choices for mild to moderate and severe symptoms?
How long do withdrawals from 7‑hydroxymitragynine last, and what can a daily user taking 300 mg expect?
In a 33-year-old male on extended-release buprenorphine/naloxone (Brixadi) who is actively using alcohol and kratom (mitragynine 20 ng/mL) and has labs showing glucose 132 mg/dL, BUN 7.8 mg/dL, chloride 97 mmol/L, CO₂ 31 mmol/L, total protein 8.4 g/dL, albumin 5.6 g/dL, cotinine 1609 ng/mL, buprenorphine 121 ng/mL, norbuprenorphine 182 ng/mL, ETG >12500 ng/mL, ETS >5000 ng/mL, sertraline >2500 ng/mL, what is the appropriate management?
If oral micronized progesterone taken at night is poorly absorbed, would increasing the dose cause daytime somnolence?
Is 1000 mg of Keflex (cephalexin) three times daily for five days an appropriate treatment for cellulitis?
Should I discontinue tirzepatide (Zepbound) because my leg pain started after taking it?
What are the etiologies and management strategies for toe necrosis in an adult (middle‑aged or older) patient with risk factors such as diabetes mellitus, smoking, peripheral arterial disease, chronic venous insufficiency, or prior foot trauma?
What dose of beta‑human chorionic gonadotropin (hCG) should be administered for a stimulation test in a pre‑pubertal boy with cryptorchidism?
What is the recommended management when definitive amputation is delayed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.